CN106318922A - Preparation method of Pfu DNA polymerase - Google Patents
Preparation method of Pfu DNA polymerase Download PDFInfo
- Publication number
- CN106318922A CN106318922A CN201610682612.2A CN201610682612A CN106318922A CN 106318922 A CN106318922 A CN 106318922A CN 201610682612 A CN201610682612 A CN 201610682612A CN 106318922 A CN106318922 A CN 106318922A
- Authority
- CN
- China
- Prior art keywords
- dna polymerase
- pfu
- archaeal dna
- preparation
- pfu archaeal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 108010002747 Pfu DNA polymerase Proteins 0.000 title abstract description 6
- 239000013612 plasmid Substances 0.000 claims abstract description 12
- 239000002773 nucleotide Substances 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims abstract description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 35
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 35
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 102000016943 Muramidase Human genes 0.000 claims description 6
- 108010014251 Muramidase Proteins 0.000 claims description 6
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 6
- 229940041514 candida albicans extract Drugs 0.000 claims description 6
- 239000012531 culture fluid Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 229960000274 lysozyme Drugs 0.000 claims description 6
- 235000010335 lysozyme Nutrition 0.000 claims description 6
- 239000004325 lysozyme Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000012137 tryptone Substances 0.000 claims description 6
- 239000012138 yeast extract Substances 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000004114 suspension culture Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- 238000010367 cloning Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000008049 TAE buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108010074858 plaferon Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention relates to the technical field of genetic engineering, in particular to a preparation method of Pfu DNA polymerase. The method includes the specific steps of firstly, cloning the nucleotide sequence shown in SEQ ID NO:1; secondly, connecting a nucleotide segment obtained in the first step with a plasmid pET32a to establish a recombinant plasmid pET32a-Pfu; thirdly, converting the recombinant plasmid pET32a-Pfu into an escherichia coli competent cell E.coli BL21 to obtain an expression strain; fourthly, conducting suspension cultivation on the expression strain through an LB culture solution, adding the IPTG with final concentration of 0.5 mM for 16-20 h after cultivation is conducted at 37 DEG C till the OD 600 value is 0.6, dissociating thallus, conducting filtering, and obtaining the recombinant Pfu DNA polymerization.
Description
Technical field
The present invention relates to gene engineering technology field, be specifically related to a kind of method preparing Pfu archaeal dna polymerase.
Background technology
1985, the polymerase chain reaction (polymerase being with historically new significance invented in Cetus company of the U.S.
Chain reaction, PCR), be a kind of method that specific DNA fragmentation is carried out in vitro rapid amplifying, i.e. double-stranded DNA exists
Under high temperature, strand is unwind in degeneration, archaeal dna polymerase, dNTP, special primer participation under, multiple according to base pair complementarity principle
Make two same molecule copies.
Archaeal dna polymerase (DNA polymerase), is the important enzyme of cell DNA duplication, is mainly used in polymerase chain
In reaction (Polymerase Chain Reaction).Archaeal dna polymerase is broadly divided into six types: A, B, C, D, X, Y, generally
Used belongs to Type B polymerase.Pfu archaeal dna polymerase is one of best polymerase of fidelity.
PfuDNA polymerase (Pfu DNA polymerase) is to find in thermophilic ancient core biology Pyrococcus, one
Class can in vivo carry out the enzyme of DNA replication dna.This enzyme contains 2 protein protomers (P45 and P50), and for polymer, molecular weight is about
90kDa.This enzyme has 5'-3' polymerase activity and 3'-5' exonuclease activity simultaneously, can correct the most in the polymerization
The base that mistake mixes, fidelity is high.In experiment in vitro, at polymerase chain reaction (polymerase chain
Reaction, PCR) in, use Pfu polymerase can be quick, the amplification of DNA fragments of high-fidelity.
Initially use Pfu archaeal dna polymerase is directly isolated and purified from thalline, but is difficult to obtain substantial amounts of enzyme, later
Its gene recombinaton is expressed in other host cell by researcher, more extracted purification can meet application requirement.According to
Described in existing document, the extraction of Pfu archaeal dna polymerase is it is generally required to two steps, and first step is breaking cellular wall, the weight that will obtain
Group the thalline methods such as ultrasonic, lysozyme or two kinds of methods combine fracturing cell walls, and this step needs ice bath low temperature, prevents
Enzyme denaturation inactivates.Second step is thermal denaturation, will broken after cell maybe will broken after cell centrifugation take supernatant and be placed in
20-30min in the water-bath of 75-80 DEG C, utilizes the thermostability of polymerase, removes remaining most of thermo-labile impurity protein, reduces
The impurity interference that subsequent purification separates, this is also the conventional extracting method of other recombinant thermostable dna polymerase.
At present Pfu archaeal dna polymerase has the sales volume of tens dollars every year in the whole world, its price the most costly, therefore
It is necessary high expressed Pfu archaeal dna polymerase system is furtherd investigate, in order to reduce production cost, and be conducive to it to push away
Extensively.
Summary of the invention
An object of the present invention is to provide the preparation method of a kind of Pfu archaeal dna polymerase, specifically comprises the following steps that
(1) clone's nucleotide sequence shown in SEQ ID NO:1；
(2) nucleotide fragments and the plasmid pET32a of step (1) gained are attached, construction recombination plasmid pET32a-
Pfu；
(3) recombiant plasmid pET32a-Pfu is transformed in competent escherichia coli cell E.coli BL21, it is thus achieved that express
Bacterial strain；
(4) expression strain utilizes LB culture fluid to carry out suspension culture, after 37 DEG C of cultivations are 0.6 to OD600 value, adds the denseest
After the IPTG that degree is 0.5mM induces 16-20 hour；Dissociate thalline, filters；Obtain restructuring Pfu archaeal dna polymerase.
In the present invention, the aminoacid sequence of described Pfu archaeal dna polymerase is known in the art, and particular sequence can be found in
Genebank accession number BAA02362.1.Nucleotide sequence SEQ ID NO:1 is the coded sequence of this aminoacid sequence, by one
Fixed is codon optimized, so that Pfu archaeal dna polymerase expression efficiency in expression system is higher.
In one embodiment, described LB culture fluid consist of tryptone 10g/L；Yeast extract 5g/L；
NaCl 10g/L；Vitamin C 0.3g/L；Glucose 1g/L；Lactose 0.1g/L；Magnesium sulfate 0.5g/L；Surplus is water, and pH value is
7.6。
In another embodiment, in step (4), described in dissociate thalline for using lysozyme to dissociate thalline；Described
It is filtered into and filters continuously with chromatographic column and bag filter.In further embodiment, the concentration of described lysozyme is 4mg/
ml；Described chromatographic column is the ion exchange column resin of Bio-Rex 70.
Accompanying drawing explanation
Pfu archaeal dna polymerase protein electrophoresis figure prepared by Fig. 1 present invention
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these examples be merely to illustrate the present invention and
It is not used in restriction the scope of the present invention.The experimental technique of unreceipted specific experiment condition in the following example, generally according to routine
Condition, Molecular Cloning: A Laboratory guide (Sambrook J, et al.2008.Molecular Cloning:A Laboratory
Manual, 3rd Ed.) described in condition, or according to the condition proposed by manufacturer.
Embodiment 1: the clone of full length gene coding region and analysis
Pfu gene (sequence is as shown in SEQ ID NO:1) and pET32a plasmid are carried out EcoRI and NotI double digestion,
After 37 DEG C of metal bath 3-4h, with 1% agarose gel electrophoresis detection, use agarose gel to reclaim test kit and reclaim.By purpose
Fragment Pfu DNA polymerase gene and plasmid pET32a are attached, and 16 DEG C overnight, and the recombiant plasmid built is named
pET32a-Pfu.Being transformed in competent escherichia coli cell E.coli BL21, it is thus achieved that expression strain, named Pfu DNA gathers
Synthase bacterial strain
The cultivation of embodiment 2:Pfu archaeal dna polymerase bacterial strain and induction
(the LB fluid medium of 500ml, is divided in the triangular flask of 2 500ml preparation LB liquid shaking bottle, the most bottled
250ml LB culture fluid, consisting of tryptone 10g/L；Yeast extract 5g/L；NaCl 10g/L；Vitamin C 0.3g/
L；Glucose 1g/L；Lactose 0.1g/L；Magnesium sulfate 0.5g/L；Surplus is water, and pH value is 7.6, lower same；After sterilizing stand-by).Take out
Pfu archaeal dna polymerase strain, is seeded in LB+Amp (the 100 μ g/ml) fluid medium of 4ml, cultivates 16-20 hour for 37 DEG C.
The LB fluid medium of the bottled 250ml of each triangle, adds Amp (the final concentration of 100 μ g/ml of antibiotic), and uses 1.25ml
Cultivation strain inoculation；After 37 DEG C are 0.6 to OD600 value, add the IPTG induction of final concentration of 0.5mM, 37 DEG C of continuation
Cultivate 16-20 hour.
Embodiment 3:Pfu archaeal dna polymerase purification utensil prepares
(size of dry powder is mesh size 100-200 to the ion exchange column resin of chromatographic column selection Bio-Rex 70.Molten
Binding ability after swollen is 5-10mg protein/ml).Weigh the dried resin of the Bio-Rex 70 of 7g, be placed in small beaker, use dd
H2O washes, and removes floating little granule, and swelling 2 hours of room temperature, period changes dd H2O several times；Pre-flat by the solution C containing 50mM KCl
Weighing apparatus, stand-by；The resin balanced by the solution C containing 50mM KCl.Install after resin again with 6-10 times of bed volume containing 50mM
The solution C balance pillar of KCl.Check that the pH value of the solution C entering pillar and flowing out pillar is constant.
Embodiment 4: Protein Extraction and purification
4 DEG C, 4000rpm, collects thalline in centrifugal 20 minutes；It is resuspended in the solution A of 30ml, rinses the thalline collected；4
DEG C, 8000rpm, collects thalline in centrifugal 10 minutes；It is resuspended in 20ml solution A, mixing.Add the lysozyme of 80mg, make the denseest
Degree reaches 4mg/ml；Keep 15 minutes under room temperature (25 DEG C)；Add the solution B of 20ml, 75 DEG C of water bath heat preservations 1 hour, period
Rock several times；4 DEG C, 10000rpm, centrifugal 20 minutes, abandons precipitation, collects supernatant；Magnetic stirrer, in supernatant
It is added dropwise over 5%PEI, makes final concentration reach 0.15% (volume)；Under room temperature, (25 DEG C) continue stirring 10 minutes；4 DEG C,
10000rpm, centrifugal 15 minutes, collects precipitation；Resuspended by the solution C containing 25mM KCl of 12ml, and wash precipitation；4 DEG C,
8000rpm, centrifugal 15 minutes, collects precipitation；Resuspended by the solution C containing 25mM KCl of 12ml, and wash precipitation；4 DEG C,
5000rpm, centrifugal 10 minutes, collects supernatant, measures the volume collecting supernatant；Add the solution without KCl of 2 times of volumes
C, makes the concentration of the final KCl of collection supernatant reach 50mM.
Supernatant is contained on the chromatographic column balanced；Chromatographic column balance uses containing of more than 6 times of volumes (about 60ml)
The solution C of 50mM KCl, balances again；The sample solution C eluting containing 200mM KCl, general preparation 50ml eluent.
Embodiment 5Pfu archaeal dna polymerase concentration measures and enzyme activity determination
(1) Pfu archaeal dna polymerase concentration uses Bradford method to be measured, with bovine serum albumin as standard, and result table
Bright purified after eluent (prepared by embodiment 4) in protein concentration be 2.9mg/ml.By Gelpro32 software analysis eluting
Liquid electrophoretogram, result shows Pfu archaeal dna polymerase high purity 95%.
(2) with calf thymus DNA as template, and with commercially available commercial Pfu archaeal dna polymerase 1U as comparison, reaction system it is
2ul (200mM Tris-HCl (PH 8.8), 100mM KCl, 100mM (NH4) 2SO4,1%Triton X-100,1mg/ml
BSA, 20mM MgSO4)；The DNA profiling of 1ul, 2ul dNTP, 1ul primer, Pfu archaeal dna polymerase (prepared by embodiment 4) and water；
PCR reaction setting see table
Result shows, Pfu archaeal dna polymerase of the present invention is compared with commercially available 1U polymerase, and enzyme is than living as 22900U/mg.
Embodiment 6 coding nucleotide sequence and the impact on Pfu archaeal dna polymerase yield of the LB culture medium
Different coding nucleotide sequences or LB culture fluid is used to repeat the preparation test of embodiment 1-4, according to enforcement
The method of example 5 measures the concentration of the Pfu archaeal dna polymerase obtained, and result is as follows:
| The concentration of Pfu archaeal dna polymerase | |
| Comparative example 1 | 0.7mg/ml |
| Comparative example 2 | 1.1mg/ml |
| Comparative example 3 | 1.6mg/ml |
| Comparative example 4 | 1.3mg/ml |
| Comparative example 5 | 1.2mg/ml |
Comparative example 1 sees the 237th-2564 bit bases in Genebank accession number D12983.1 for coding nucleotide sequence
Sequence, other preparation methoies are with embodiment 1-4
Comparative example 2 sees nucleotide sequence disclosed in Genebank accession number KF836420.1 for coding nucleotide sequence,
Other preparation methoies are with embodiment 1-4
Comparative example 3 is tryptone 10g/L for LB culture medium；Yeast extract 5g/L；NaCl 10g/L；Glucose 1g/
L；Lactose 0.1g/L；Magnesium sulfate 0.5g/L；Surplus is water, and pH value is 7.6, and other preparation methoies are with embodiment 1-4
Comparative example 4 is tryptone 10g/L for LB culture medium；Yeast extract 5g/L；NaCl 10g/L；Lactose 0.1g/
L；Magnesium sulfate 0.5g/L；Surplus is water, and pH value is 7.6, and other preparation methoies are with embodiment 1-4
Comparative example 5 is tryptone 10g/L for LB culture medium；Yeast extract 5g/L；NaCl 10g/L；Vitamin C
0.3g/L；Glucose 1g/L；Lactose 0.1g/L；Magnesium sulfate 0.5g/L；Surplus is water, and pH value is 7.0, and other preparation methoies are with real
Execute example 1-4
Related solution formula is as follows:
Solution A formulation: 5ml 1 M Tris-HCl, pH 8.0；0.9g Dextrose(glucose)；0.2ml 0.5M
EDTA；The ddH20 adding sterilizing is 100ml to volume.
Solution B formula: 10mM Tris (pH 8.0)；50mM KCl；1mM EDTA；1mM PMSF；0.5%Tween20；
0.5%NP-40；The ddH20 adding sterilizing is 100ml to volume.
4 × solution C formula: 20mM HEPES (pH 7.9)；1mM EDTA；0.5mM PMSF；0.5%Tween 20；0.
5%NP-40；The ddH20 adding sterilizing is 250ml to volume.
4 × solution D formula: 20mM HEPES (pH 7.9)；100mM KCl；0.1mM EDTA；0.5mM PMSF；1mM
DTT；The ddH20 adding sterilizing is 250ml to volume.
1 × PCR reaction buffer formula: 500mM KCl, 100mM Tris-HCl, pH 9.0 (25 DEG C), 20mM
MgCl2,0.1% gelatin, 1%Triton X-100.
1 × TAE buffer: dilute with 50 × TAE buffer mother solution.Tris alkali 242g, glacial acetic acid 57.1ml,
Na2EDTA 2H2O 37.2g, the ddH20 adding sterilizing is 1000ml to volume.
Although the present invention describes specific example, but has any will be apparent to practitioners skilled in the art,
The present invention can be made various changes and change the most under the premise without departing from the spirit and scope of the present invention.Therefore, appended right
Require to cover all these variation within the scope of the present invention.
Claims (5)
1. a preparation method for Pfu archaeal dna polymerase, specifically comprises the following steps that
(1) clone's nucleotide sequence shown in SEQ ID NO:1；
(2) nucleotide fragments and the plasmid pET32a of step (1) gained are attached, construction recombination plasmid pET32a-Pfu；
(3) recombiant plasmid pET32a-Pfu is transformed in competent escherichia coli cell E.coli BL21, it is thus achieved that express bacterium
Strain；
(4) expression strain utilizes LB culture fluid to carry out suspension culture, after 37 DEG C of cultivations are 0.6 to OD600 value, adds final concentration of
After the IPTG of 0.5mM induces 16-20 hour；Dissociate thalline, filters；Obtain restructuring Pfu archaeal dna polymerase.
The preparation method preparing Pfu archaeal dna polymerase the most according to claim 1, it is characterised in that described LB culture fluid
Consist of tryptone 10g/L；Yeast extract 5g/L；NaCl 10g/L；Vitamin C 0.3g/L；Glucose 1g/L；Breast
Sugar 0.1g/L；Magnesium sulfate 0.5g/L；Surplus is water, and pH value is 7.6.
The preparation method preparing Pfu archaeal dna polymerase the most according to claim 1, it is characterised in that in step (4),
The described thalline that dissociates is for using lysozyme to dissociate thalline；Described being filtered into is filtered continuously with chromatographic column and bag filter.
The preparation method preparing Pfu archaeal dna polymerase the most according to claim 3, it is characterised in that described lysozyme
Concentration is 4mg/ml.
The preparation method preparing Pfu archaeal dna polymerase the most according to claim 3, it is characterised in that described chromatographic column is
The ion exchange column resin of Bio-Rex70.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610682612.2A CN106318922A (en) | 2016-08-17 | 2016-08-17 | Preparation method of Pfu DNA polymerase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610682612.2A CN106318922A (en) | 2016-08-17 | 2016-08-17 | Preparation method of Pfu DNA polymerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106318922A true CN106318922A (en) | 2017-01-11 |
Family
ID=57742964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610682612.2A Pending CN106318922A (en) | 2016-08-17 | 2016-08-17 | Preparation method of Pfu DNA polymerase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106318922A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662893A (en) * | 2020-07-01 | 2020-09-15 | 济南国科医工科技发展有限公司 | Preparation method of molecular diagnostic enzyme preparation |
| CN114015672A (en) * | 2021-12-06 | 2022-02-08 | 江南大学 | A kind of Pfu DNA polymerase |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103602643A (en) * | 2013-11-18 | 2014-02-26 | 青岛思能基因生物技术有限公司 | Recombinant Taq DNA polymerase and preparation method thereof |
-
2016
- 2016-08-17 CN CN201610682612.2A patent/CN106318922A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103602643A (en) * | 2013-11-18 | 2014-02-26 | 青岛思能基因生物技术有限公司 | Recombinant Taq DNA polymerase and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| AKBARZADEH,A., ET AL.: "Genbank accession number:KF836420.1", 《GENBANK》 * |
| UEMORI, T., ET AL.: "Genbank accession number:D12983.1", 《GENBANK》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662893A (en) * | 2020-07-01 | 2020-09-15 | 济南国科医工科技发展有限公司 | Preparation method of molecular diagnostic enzyme preparation |
| CN114015672A (en) * | 2021-12-06 | 2022-02-08 | 江南大学 | A kind of Pfu DNA polymerase |
| CN114015672B (en) * | 2021-12-06 | 2022-05-31 | 江南大学 | Pfu DNA polymerase |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103602643B (en) | Recombinant Taq DNA polymerase and preparation method thereof | |
| CN117660396A (en) | DNA polymerase mutant | |
| CN112063643A (en) | Expression vector and method for detecting interaction of membrane proteins in bacteria | |
| CN109402092B (en) | A marine environment-derived chitinase and its gene | |
| CN106318922A (en) | Preparation method of Pfu DNA polymerase | |
| CN102021173B (en) | Preparation method for soluble truncated human tumor necrosis factor-related apoptosis inducing ligand (TRAIL) active protein | |
| WO2017148163A1 (en) | Method for extracting 2',3'-cyclic nucleoside monophosphates | |
| CN119351373A (en) | Endonuclease and its application | |
| CN108486142A (en) | A kind of construction method of the genetic engineering bacterium of expression prenyltransferase ComQ and application | |
| CN111019922B (en) | Mutant restriction enzyme BsaI and preparation method and application thereof | |
| CN110628802B (en) | Sorangium cellulosum for high-yield epothilone D and construction method and application thereof | |
| CN114230644A (en) | GP32 protein mutant, recombinant vector, and construction method and application thereof | |
| CN114381443A (en) | Preparation method of Deep Vent (exo-) DNA polymerase | |
| WO2021253521A1 (en) | Artificial non-coding rna module for enhancing nitrogen fixation capability of microorganisms | |
| CN117586991B (en) | β-N-acetylhexosaminidase FlaNag2353 and its application | |
| CN106086040B (en) | A marine bacterial gene LfliZ and its application | |
| CN117821484A (en) | Preparation method and application of HindIII restriction enzyme | |
| CN102827829A (en) | Preparation method of desoxyribonucleic acid probe for fluorescence in-situ hybridization | |
| CN119662614A (en) | A recombinant purine nucleoside deaminase and its application | |
| CN117778436A (en) | Process for efficiently preparing soluble RNase inhibitor | |
| CN115975987A (en) | Preparation method of AscI restriction endonuclease | |
| CN118853520A (en) | Recombinant halophilic bacteria producing Taq DNA polymerase and construction method and application thereof | |
| CN108251345B (en) | Recombinant engineering bacterium containing lipase gene for domestic sewage treatment and construction method thereof | |
| CN106566819B (en) | A kind of low temperature halophilic alpha-amylase gene cloning, expression and separation and purification method | |
| CN112280763A (en) | Production method of recombinant nicking restriction enzyme in escherichia coli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |